New funding will support assay development and lab space to offer test services, and ultimately a test kit using the firm's resistance database.
Researchers showed that the test had equivalent results to a lab-based assay and has the potential for a faster turnaround time.
Despite a recent positive economic modeling study, the debate over appropriate use of the ME panel seems likely to continue until more outcomes studies are conducted.
The research highlighted particular challenges for gram-negative organisms among a population of higher-risk patients.
ChromaCode this week launched its first product, a research-use-only test for nine tick-borne pathogens designed for research use on any thermal cycler.
The firm is wrapping up a pre-order period and recently signed a distribution deal with D-Mark Bioscience for the new instrument, called Liberty16.
Researchers hope that understanding the etiology of inappropriate testing will help them design a better computerized support tool.
In the firm's first-ever earnings call, new CEO Jack Kenny said the firm will invest more in R&D to revamp its aging portfolio.
The Elite InGenius has the sample prep capabilities typical of high-throughput platforms, yet it can run more samples than smaller instruments.
Columbia University researchers have adapted a capture-based targeted sequencing method for viral genomes to detect bacteria in clinical samples.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.